Traws Pharma, Inc. (TRAW): Nasdaq/NYSE listing notice — Onconova receives Nasdaq bid price deficiency notice; 180-day cure period to March 2024

Traws Pharma, Inc.

Received Nasdaq notice on Sep 25, 2023 for failure to maintain $1.00 minimum bid price.
Has until March 25, 2024 to regain compliance with closing bid >=$1 for 10 consecutive days.
If not cured, may qualify for second 180-day period by meeting other standards and notifying intent to reverse split.
Company says it will monitor options but cannot assure compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Traws Pharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

September 25, 2023, the Company received a letter from The Nasdaq Capital Market (“Nasdaq”) indicating that the Company has failed to comply with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5550(a) (2) requires that companies listed on Nasdaq maintain a minimum closing bid price of at least $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a 180 calendar day grace period, or until March 25, 2024, to regain compliance by meeting the continued listing standard. The continued listing standard will be met if the Company’s common

View on SEC.gov

Browse all listing & compliance notices →

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-105381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.